MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics

MeiraGTx Holdings plc - Ordinary Shares (MGTX)

Today's Latest Price: $18.06 USD

0.82 (-4.34%)

Updated Feb 18 8:00pm

Add MGTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MGTX Daily Price Range
MGTX 52-Week Price Range

MGTX Stock Price Chart More Charts

MGTX Price/Volume Stats

Current price $18.06 52-week high $30.23
Prev. close $18.88 52-week low $12.00
Day low $17.91 Volume 122,400
Day high $18.95 Avg. volume 113,688
50-day MA $20.01 Dividend yield N/A
200-day MA $20.39 Market Cap 660.49M

MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio

MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.

MGTX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for MeiraGTx Holdings plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that MeiraGTx Holdings plc ranked in the 0st percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for MeiraGTx Holdings plc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 0.48 years, is -0.66% -- higher than only 0.76% of stocks in our DCF forecasting set.
  • As a business, MGTX is generating more cash flow than only 22.93% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 13.12% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

AGHC, ALC, CSII, ENZ, and HAPP can be thought of as valuation peers to MGTX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

MGTX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MGTX Latest Social Stream

Loading social stream, please wait...

View Full MGTX Social Stream

MGTX Price Returns

1-mo N/A
3-mo 5.80%
6-mo -16.16%
1-year 40.98%
3-year N/A
5-year N/A
YTD -9.79%
2019 107.68%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.679 seconds.